Takeda Aims At BMS’s Sotyktu In $4bn Deal For Nimbus’s TYK2 Inhibitor
Takeda’s R&D chief Andy Plump said his company has seen data indicating game-changing characteristics for TAK-279 in psoriasis. It plans to bring the candidate into Phase III next year.
You may also be interested in...
Record Revenues For Takeda But Headwinds Coming
While Japan's largest pharma company reached a number of milestones last fiscal year, it is facing a number of challenges to revenues in 2023, for which it is looking to its core commercial portfolio and pipeline to help drive growth.
Building On Successes During Turbulent Times, SR One Closes $600m Fund II
SR One will keep investing in a mix of new companies, early-stage firms and later opportunities with its second fund, raised even as biotech continues to endure challenging financial times.
Takeda’s High-Dose TYK2 Data Could Set It Apart In Psoriasis
Safety and efficacy data show that as long as Takeda can execute effectively on a Phase III program for TAK-279, the company should be well positioned in the oral psoriasis market.